Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
Veids | 3.1. Papildu regulētā informācija, kas ir jāatklāj saskaņā ar dalībvalsts tiesību aktiem |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2018-08-22 11:38:17 |
Versijas komentārs | |
Teksts |
On Wednesday, August 22, the leaders of Latvian science and industry – JSC “Grindeks” and Latvian Institute of Organic Synthesis (IOS) – strengthened their long-lasting partnership with a new agreement, to reorient from the individual research projects to the strategic long-term cooperation and to open up new perspective to the drug research and development. The purpose of the agreement is to make the current partnership of both parties even closer, which will serve for meeting the demand of global pharmaceutical market with more efficiency and productivity, and helping to develop new medications for the improvement of public health. Juris Bundulis, Chairman of the Board of JSC “Grindeks”, also maintained that cultivating close and productive cooperation in the development field is one of the keystones of the business growth in the pharmaceutical industry. “The Latvian Institute of Organic Synthesis has a team of the world’s top scientists in the field of new drug research. At “Grindeks”, one of the most experienced pharmaceutical companies in Latvia, we find it essential to team up with excellent local scientists especially, and therefore to keep investments in Latvia which contributes to our country’s economic growth,” Juris Bundulis, Chairman of the Board of JSC “Grindeks” noted. At the event, the Chairman of the Council of JSC “Grindeks” Kirovs Lipmans delivered a speech, while the director of IOS Osvalds Pugovics presented the activities of the institute and cooperation with the industry. The Head of Laboratory of Pharmaceutical Pharmacology of IOS Maija Dambrova presented the most recent history of the joint project of “Grindeks” and the institute. Chairman of the Board of JSC “Grindeks” Juris Bundulis outlined the company’s perspective of cooperation with scientists, while Deputy Director of the Higher Education, Science and Innovation Department at the Latvian Ministry of Education and Science Dmitrijs Stepanovs presented the state support to the science. Andris Ozols, General Director of the Investment Development Agency of Latvia presented the opportunities of accessible funds for export-capable product development. The most significant current project managed by “Grindeks” in cooperation with Latvian scientists is the research of a new drug candidate for the treatment of cardiovascular diseases, expected to be the first newly developed medicine in Latvia since the 1980s. Event photo gallery: https://failiem.lv/u/nrm2npj9 About “Grindeks” About IOS Further information: |
Pielikumi |
|